Kyverna Therapeutics, Inc. KYTX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s stock issuance proceeds?
- Kyverna Therapeutics, Inc. (KYTX) reported stock issuance proceeds of $243K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Kyverna Therapeutics, Inc.'s stock issuance proceeds increased by 8000.0% year-over-year, from $3K to $243K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s stock issuance proceeds?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s stock issuance proceeds has grown at a 412.5% compound annual growth rate (CAGR), from $645K to $16.94M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.